Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate

Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate
Skip the menu
ホーム
>
PR
>
Press Release Articles
> Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate
Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate
May. 14, 2024
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; "Sumitomo Pharma") and National Institutes of Biomedical Innovation, Health and Nutrition (Ibaraki, Osaka, Japan; President: Yusuke Nakamura; "NIBIOHN") have been working on the development of a universal influenza vaccine with prophylactic efficacy against a wide range of influenza viruses under the Cyclic Innovation for Clinical Empowerment program conducted by Japan Agency for Medical Research and Development .
Sumitomo Pharma and NIBIOHN announced today that they have commenced a Phase 1 clinical study on "fH1/DSP-0546LP", a universal influenza vaccine candidate formulation, in Europe.
Press Release Materials
（181KB）
トップページ「What's New」欄に表示する画像
Achievement ／ Events ／ News
のいずれかを入力してください。
Achievement
PR
Press Release Articles
Non-Press Release Articles